An antibiotic commonly prescribed for bronchitis and sinus infections may increase the risk of death from heart problems, but only for people with certain risk factors, a new study suggests. The study ...

Patients taking azithromycin should not stop taking it without consulting a clinician, the FDA added. The issue of macrolides and the risk for cardiovascular death has been on the FDA's radar since ...

At IDWeek, 2025, held on 19–22 October, Dr Sarah McLeod from Innoviva Specialty Therapeutics presented subgroup analyses from a global Phase III noninferiority randomised controlled trial which ...

Mass administration of azithromycin to both infants aged 1-11 months and children aged 12-59 months reduced infant mortality compared with treating infants alone. Although the interaction effect was ...

Findings showed zoliflodacin was noninferior to ceftriaxone plus azithromycin (microbiological cure rate, 90.9% vs 96.2%, respectively; difference, 5.3%). The Food and Drug Administration (FDA) has ...